Roivant reports Q1 fiscal 2027 results, pipeline on track across four vants

Roivant said commercial preparations for brepocitinib in dermatomyositis are progressing well and remain on track for launch by the end of September 2026¹. Separately, the company disclosed that patients have begun enrolling in a Phase 3 study of brepocitinib in cutaneous sarcoidosis, following a Phase 2 study that produced the first positive placebo-controlled results in the disease and led to FDA Breakthrough Therapy Designation¹.

That new trial, called BEACON+, is designed as Part B of the earlier BEACON study and plans to enroll about 140 patients with cutaneous sarcoidosis at roughly 70 sites globally, randomizing patients 3:2 between 45mg brepocitinib once daily and placebo, with the primary endpoint being a 50% or greater reduction in the CSAMI-A score at Week 16¹. In the Phase 2 trial, 77% of patients on the 45mg dose met that endpoint versus 0% on placebo¹. The company noted there are currently no FDA-approved therapies for cutaneous sarcoidosis¹.

Roivant also said enrollment in Part 1 of its Phase 2b/3 study in lichen planopilaris is progressing well¹, and that clinical timelines for IMVT-1402 remain on track across its announced indications, including a proof-of-concept trial in cutaneous lupus erythematosus¹. The company confirmed its Phase 2 study of mosliciguat in PH-ILD remains on track¹, with topline data expected in the second half of calendar year 2026¹. On litigation, Genevant and Arbutus received $950 million from Moderna in July 2026, the first payment under a $2.25 billion settlement, and filed new lawsuits against Pfizer and BioNTech¹, with an additional $1.3 billion contingent on a favorable outcome of Moderna's Section 1498 appeal¹.

Financially, Roivant reported $3.9 billion in consolidated cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026, not including the July Moderna payment, which it said supports its runway into profitability¹.